Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 18/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.56 |
| ▸ | SRC | P12931 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12619259 | 0.87 | AURKA (0.58) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL13963094 | 0.81 | AURKA (0.70) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL802209 | 0.80 | AURKA (0.82) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL801563 | 0.79 | AURKA (0.73) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL802544 | 0.79 | AURKA (0.60) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL12653547 | 0.79 | AURKA (0.60) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL802152 | 0.78 | AURKA (0.76) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL802151 | 0.74 | AURKA (0.76) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL29435815 | 0.73 | AURKA (1.00) | AURKAAURKBSRCGSK3BEIF2AK2 | |
| SCHEMBL462877 | 0.73 | AURKA (1.00) | AURKAAURKBSRCGSK3BEIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | AURKA 8/4885AURKB 19/4885SRC 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.